Entheon Biomedical Corp. Welcomes Harrison Newlands to its Board of Directors
Vancouver, British Columbia – April 4, 2025 – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU) (“Entheon” or the “Company”), a biotech company focused on developing psychedelic medicines, is thrilled to announce the appointment of Harrison Newlands to its Board of Directors, effective April 3, 2025.
Experience and Expertise
Harrison Newlands brings a wealth of experience and knowledge to Entheon’s Board. With a diverse understanding of start-ups and capital markets, he has spent nearly a decade investing, advising, and helping co-found dozens of mid-cap companies. His extensive experience in the industry will be invaluable as Entheon continues to grow and develop its psychedelic medicines.
Entheon’s Continued Growth
Entheon’s appointment of Harrison Newlands is a significant step forward for the company. With a strong leadership team and a focus on innovation, Entheon is well-positioned to make a meaningful impact in the psychedelic medicines industry. Newlands’ expertise in capital markets and start-ups will help Entheon secure the necessary funding to continue its research and development efforts.
Impact on Individuals
For individuals struggling with mental health conditions such as depression, anxiety, and PTSD, Entheon’s work in developing psychedelic medicines could be life-changing. These conditions can be debilitating, and current treatments often fall short in providing lasting relief. Entheon’s innovative approach to psychedelic medicines holds great promise in addressing these unmet needs.
Impact on the World
The appointment of Harrison Newlands to Entheon’s Board of Directors is a positive sign for the psychedelic medicines industry as a whole. With increasing recognition of the potential benefits of psychedelic medicines, there is growing investment and interest in the field. Entheon’s progress in developing these medicines could lead to new treatments for mental health conditions, reducing the burden on individuals and healthcare systems around the world.
Conclusion
Entheon Biomedical Corp.’s appointment of Harrison Newlands to its Board of Directors is an exciting development for the company and the psychedelic medicines industry. Newlands’ extensive experience in capital markets and start-ups will help Entheon secure the necessary funding to continue its research and development efforts. For individuals struggling with mental health conditions and for the world as a whole, Entheon’s work in developing psychedelic medicines holds great promise in providing lasting relief and reducing the burden on healthcare systems.
- Entheon Biomedical Corp. appoints Harrison Newlands to its Board of Directors
- Newlands brings diverse experience in start-ups and capital markets
- Entheon well-positioned to make impact in psychedelic medicines industry
- Individuals with mental health conditions could benefit from Entheon’s work
- World could see reduced burden on healthcare systems with new treatments
